Compound Notes 4 min read
MOTS-c: The Clinical Picture of the First Mitokine
A measured clinical summary of MOTS-c, the 16-amino-acid peptide encoded inside mitochondrial DNA, what the published research actually shows in animal models and early human work, and where the compound sits in a longevity-context protocol.
Last reviewed: May 2026
MOTS-c is a 16-amino-acid peptide. It is one of a small family of mitochondrial-derived peptides, encoded inside the 12S rRNA region of the mitochondrial genome rather than the nuclear genome. The name is an acronym for “mitochondrial open reading frame of the 12S rRNA type-c.” It was first characterised by Changhan Lee and colleagues in Pinchas Cohen’s lab at USC, with the foundational paper published in Cell Metabolism in 2015. The discovery opened a category of signalling molecules the field now calls mitokines: peptides produced by mitochondria that travel in plasma and signal to distant tissues.
The clinical picture, summarised plainly: MOTS-c is one of the better-characterised research compounds in the longevity-peptide space, with a real animal-research base, early human data that is broadly favourable, and a hypothesised mechanism that fits cleanly into the broader hallmarks-of-aging framework.
Mechanism
MOTS-c acts on multiple cellular pathways involved in metabolic regulation. The cleanest documented effects are on AMPK signalling (the cellular energy-sensing pathway) and on insulin sensitivity. In skeletal muscle, MOTS-c improves glucose disposal and supports metabolic flexibility. In the broader systemic picture, the compound interacts with mTOR signalling and with the cellular response to metabolic stress.
The compound also moves to the nucleus under certain conditions. This is unusual for a peptide of its class. The nuclear localisation suggests a role in regulating nuclear gene expression in response to mitochondrial signals. The picture is still being worked out at the molecular level, but the broad outline is consistent: mitochondria use MOTS-c to communicate metabolic state to the rest of the cell and to other tissues.
Animal-model evidence
Mice given MOTS-c show improved insulin sensitivity, reduced fat-mass accumulation on high-fat diet, and improved exercise capacity. The improvements are most pronounced in older animals. In some studies, MOTS-c administration partially restored age-related declines in metabolic flexibility. The pattern is consistent across multiple labs and multiple model systems.
Importantly, MOTS-c is one of the compounds where endogenous levels decline with age. Plasma MOTS-c is lower in older adults than younger adults. This is the inverse of the typical hormone story (where systemic levels often rise with age in compensatory ways) and aligns with the broader mitochondrial-dysfunction story covered in our mitochondrial health piece.
Human evidence
Human research on MOTS-c is earlier-stage than the animal research. Pilot studies in metabolically compromised cohorts have shown favourable shifts in insulin sensitivity and metabolic markers at research-protocol doses. The studies are small. The protocols are heterogeneous. The compound has not yet been through the kind of large randomised controlled trial that would settle questions of effect size and durability.
This is the gap that should set buyer expectations. The animal data is strong. The human data is consistent in direction but limited in scale. A serious researcher considering MOTS-c should hold both pieces in mind: the case for inclusion in a longevity-context protocol is reasonable, and the certainty of effect for any individual is moderate at best.
Research-protocol patterns
Standard subcutaneous protocol patterns for MOTS-c run 5 to 10 mg per administration, two to four times per week, in 8 to 12 week cycles. Some research protocols use shorter, higher-dose courses. Others use longer, more conservative dosing. The optimal pattern for any specific outcome has not been established at clinical-trial scale.
Reconstitution follows the standard lyophilised-peptide pattern. The Dosage Calculator handles the syringe-units conversion. Storage follows the same rules as other peptides: lyophilised vials at room temperature, reconstituted vials at 2 to 8°C, 28-day stability after reconstitution.
What pairs with MOTS-c
MOTS-c sits in the longevity stack alongside compounds that address related cellular-aging hallmarks:
- NAD+ for the cofactor pathway that mitochondria require for electron transport
- Epitalon as the cellular-aging adjunct, with the limitations described in our Epitalon piece
- Hydra Core for the electrolyte-and-hydration support that pairs with active research-context protocols
The Protocol Builder Longevity goal includes MOTS-c in the curated stack.
The clinical line
MOTS-c is research-grade only, sold for laboratory and research use. It is not approved as a medicine. It is not a licensed dietary supplement. Whether the compound belongs in your specific situation, at what dose, for how long, is a clinical question that belongs with a UAE-licensed healthcare professional who knows your full medical context.
The summary
MOTS-c is one of the better-characterised mitochondrial peptides available in the research catalogue. The mechanism is grounded in real molecular biology. The animal evidence is strong. The human evidence is preliminary but favourable in direction. The compound earns its place in a longevity-context protocol with realistic expectations and the standard research-context posture.